The quest for diagnostic molecular markers for thyroid nodules with indeterminate or suspicious cytology

Journal of Surgical Oncology

Volumn 105, Issue 5, 2012, Pages 438-443

  Kouniavsky, Guennadi ^a,b   Zeiger, Martha A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

fine needle aspiration

Indexed keywords

B RAF KINASE; CHEMOKINE RECEPTOR CXCR4; CYTOKERATIN 19; GALECTIN 3; HECTOR BATTIFORA MESOTHELIAL CELL 1 MONOCLONAL ANTIBODY; HIGH MOBILITY GROUP A2 PROTEIN; MICRORNA; MOLECULAR MARKER; MONOCLONAL ANTIBODY; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN RET; RAS PROTEIN; SOMATOMEDIN BINDING PROTEIN 3; TELOMERASE REVERSE TRANSCRIPTASE; THYROTROPIN RECEPTOR; TREFOIL FACTOR 3; TREFOIL PEPTIDE; UBIQUITIN CONJUGATING ENZYME; UNCLASSIFIED DRUG;

ASPIRATION BIOPSY; CYTODIAGNOSIS; CYTOLOGY; CYTOPATHOLOGY; DIAGNOSTIC VALUE; GENE MUTATION; GENE REARRANGEMENT; MOLECULAR DIAGNOSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; THYROID NODULE; THYROID PAPILLARY CARCINOMA;

ALTERNATIVE SPLICING; BIOPSY, FINE-NEEDLE; CHROMOSOME ABERRATIONS; DIAGNOSIS, DIFFERENTIAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REARRANGEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; MICRORNAS; MUTATION; OBSERVER VARIATION; POLYMERASE CHAIN REACTION; PROTEIN ARRAY ANALYSIS; THYROID NODULE; TRANSLATIONAL MEDICAL RESEARCH; TUMOR MARKERS, BIOLOGICAL;

EID: 84859092085     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21935     Document Type: Review

References (89)

1. Cooper DS, Doherty GM, Haugen BR, et al.: Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167-1214.
2. Banks ND, Kowalski J, Tsai HL, et al.: A diagnostic predictor model for indeterminate or suspicious thyroid FNA samples. Thyroid 2008; 18: 933-941.
3. Marchevsky AM, Walts AE, Bose S, et al.: Evidence-based evaluation of the risks of malignancy predicted by thyroid fine-needle aspiration biopsies. Diagn Cytopathol 2010; 38: 252-259.
4. Piana S, Frasoldati A, Ferrari M, et al.: Is a five-category reporting scheme for thyroid fine needle aspiration cytology accurate? Experience of over 18 000 FNAs reported at the same institution during 1998-2007. Cytopathology, no. DOI: 10.1111/j.1365-2303.2010.00777.x
5. Nayar R, Ivanovic M,: The indeterminate thyroid fine-needle aspiration: Experience from an academic center using terminology similar to that proposed in the 2007 National Cancer Institute Thyroid Fine Needle Aspiration State of the Science Conference. Cancer Cytopathol 2009; 117: 195-202.
6. Yassa L, Cibas ES, Benson CB, et al.: Long-term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation. Cancer 2007; 111: 508-516. (Pubitemid 350304903)
7. Baloch ZW, LiVolsi VA, Asa SL, et al.: Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: A synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn Cytopathol 2008; 36: 425-437. (Pubitemid 351829800)
8. Xing M,: BRAF mutation in papillary thyroid cancer: Pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007; 28: 742-762. (Pubitemid 350294294)
9. Kebebew E, Weng J, Bauer J, et al.: The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 2007; 246: 466-470; discussion 470-471. (Pubitemid 47312140)
10. Ito Y, Yoshida H, Maruo R, et al.: BRAF mutation in papillary thyroid carcinoma in a Japanese population: Its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J 2009; 56: 89-97.
11. Xing M, Clark D, Guan H, et al.: BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol 2009; 27: 2977-2982.
12. Sapio MR, Guerra A, Posca D, et al.: Combined analysis of galectin-3 and BRAFV600E improves the accuracy of fine-needle aspiration biopsy with cytological findings suspicious for papillary thyroid carcinoma. Endocr Relat Cancer 2007; 14: 1089-1097. (Pubitemid 351252440)
13. Nikiforov YE, Steward DL, Robinson-Smith TM, et al.: Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab 2009; 94: 2092-2098.
14. Ohori NP, Nikiforova MN, Schoedel KE, et al.: Contribution of molecular testing to thyroid fine-needle aspiration cytology of "follicular lesion of undetermined significance/atypia of undetermined significance. " Cancer Cytopathol 2010; 118: 17-23.
15. Cantara S, Capezzone M, Marchisotta S, et al.: Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. J Clin Endocrinol Metab 2010; 95: 1365-1369.
16. Nikiforova MN, Lynch RA, Biddinger PW, et al.: RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: Evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 2003; 88: 2318-2326. (Pubitemid 36549913)
17. Gregory Powell J, Wang X, Allard BL, et al.: The PAX8/PPARgamma fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPARgamma inhibition. Oncogene 2004; 23: 3634-3641. (Pubitemid 38658430)
18. Castro P, Rebocho AP, Soares RJ, et al.: PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab 2006; 91: 213-220. (Pubitemid 43069140)
19. Algeciras-Schimnich A, Milosevic D, McIver B, et al.: Evaluation of the PAX8/PPARG translocation in follicular thyroid cancer with a 4-color reverse-transcription PCR assay and automated high-resolution fragment analysis. Clin Chem 2010; 56: 391-398.
20. Guerriero E, Ferraro A, Desiderio D, et al.: UbcH10 expression on thyroid fine-needle aspirates. Cancer Cytopathol 2010; 118: 157-165.
21. Chiappetta G, Ferraro A, Vuttariello E, et al.: HMGA2 mRNA expression correlates with the malignant phenotype in human thyroid neoplasias. Eur J Cancer 2008; 44: 1015-1021.
22. Belge G, Meyer A, Klemke M, et al.: Upregulation of HMGA2 in thyroid carcinomas: A novel molecular marker to distinguish between benign and malignant follicular neoplasias. Genes Chromosomes Cancer 2008; 47: 56-63. (Pubitemid 350191464)
23. Prasad NB, Somervell H, Tufano RP, et al.: Identification of genes differentially expressed in benign versus malignant thyroid tumors. Clin Cancer Res 2008; 14: 3327-3337.
24. Lappinga PJ, Kip NS, Jin L, et al.: HMGA2 gene expression analysis performed on cytologic smears to distinguish benign from malignant thyroid nodules. Cancer Cytopathol 2010; 118: 287-297.
25. Wang Y, Kowalski J, Tsai HL, et al.: Differentiating alternative splice variant patterns of human telomerase reverse transcriptase in thyroid neoplasms. Thyroid 2008; 18: 1055-1063.
26. Foukakis T, Gusnanto A, Au AY, et al.: A PCR-based expression signature of malignancy in follicular thyroid tumors. Endocr Relat Cancer 2007; 14: 381-391. (Pubitemid 47242637)
27. Weber F, Teresi RE, Broelsch CE, et al.: A limited set of human MicroRNA is deregulated in follicular thyroid carcinoma. J Clin Endocrinol Metab 2006; 91: 3584-3591. (Pubitemid 44402141)
28. Pallante P, Visone R, Ferracin M, et al.: MicroRNA deregulation in human thyroid papillary carcinomas. Endocr Relat Cancer 2006; 13: 497-508. (Pubitemid 43886672)
29. Nikiforova MN, Tseng GC, Steward D, et al.: MicroRNA expression profiling of thyroid tumors: Biological significance and diagnostic utility. J Clin Endocrinol Metab 2008; 93: 1600-1608. (Pubitemid 351656494)
30. Takano T, Yamada H,: Trefoil factor 3 (TFF3): A promising indicator for diagnosing thyroid follicular carcinoma. Endocr J 2009; 56: 9-16.
31. Patel MR, Bryson PC, Shores CG, et al.: Trefoil factor 3 immunohistochemical characterization of follicular thyroid lesions from tissue microarray. Arch Otolaryngol Head Neck Surg 2009; 135: 590-596.
32. Bryson PC, Shores CG, Hart C, et al.: Immunohistochemical distinction of follicular thyroid adenomas and follicular carcinomas. Arch Otolaryngol Head Neck Surg 2008; 134: 581-586. (Pubitemid 351871015)
33. Liu FT, Rabinovich GA,: Galectins as modulators of tumour progression. Nat Rev Cancer 2005; 5: 29-41. (Pubitemid 40052323)
34. Bartolazzi A, Orlandi F, Saggiorato E, et al.: Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: A prospective multicentre study. Lancet Oncol 2008; 9: 543-549.
35. Torregrossa L, Faviana P, Filice ME, et al.: CXC chemokine receptor 4 immunodetection in the follicular variant of papillary thyroid carcinoma: Comparison to galectin-3 and Hector Battifora mesothelial cell-1. Thyroid 2010; 20: 495-504.
36. Saggiorato E, De Pompa R, Volante M, et al.: Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: A proposal for clinical application. Endocr Relat Cancer 2005; 12: 305-317. (Pubitemid 40896449)
37. Raggio E, Camandona M, Solerio D, et al.: The diagnostic accuracy of the immunocytochemical markers in the preoperative evaluation of follicular thyroid lesions. J Endocrinol Invest 2010; 33: 378-381.
38. Franco C, Martinez V, Allamand JP, et al.: Molecular markers in thyroid fine-needle aspiration biopsy: A prospective study. Appl Immunohistochem Mol Morphol 2009; 17: 211-215.
39. Khurana KK, Truong LD, LiVolsi VA, et al.: Cytokeratin 19 immunolocalization in cell block preparation of thyroid aspirates. An adjunct to fine-needle aspiration diagnosis of papillary thyroid carcinoma. Arch Pathol Lab Med 2003; 127: 579-583. (Pubitemid 36534942)
40. Beesley MF, McLaren KM,: Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules. Histopathology 2002; 41: 236-243. (Pubitemid 35013945)
41. Slosar M, Vohra P, Prasad M, et al.: Insulin-like growth factor mRNA binding protein 3 (IMP3) is differentially expressed in benign and malignant follicular patterned thyroid tumors. Endocr Pathol 2009; 20: 149-157.
42. Jin L, Seys AR, Zhang S, et al.: Diagnostic utility of IMP3 expression in thyroid neoplasms: A quantitative RT-PCR study. Diagn Mol Pathol 2010; 19: 63-69.
43. Hoftijzer HC, Liu YY, Morreau H, et al.: Retinoic acid receptor and retinoid X receptor subtype expression for the differential diagnosis of thyroid neoplasms. Eur J Endocrinol 2009; 160: 631-638.
44. Troncone G, Volante M, Iaccarino A, et al.: Cyclin D1 and D3 overexpression predicts malignant behavior in thyroid fine-needle aspirates suspicious for Hurthle cell neoplasms. Cancer Cytopathol 2009; 117: 522-529.
45. Chia SY, Milas M, Reddy SK, et al.: Thyroid-stimulating hormone receptor messenger ribonucleic acid measurement in blood as a marker for circulating thyroid cancer cells and its role in the preoperative diagnosis of thyroid cancer. J Clin Endocrinol Metab 2007; 92: 468-475.
46. Milas M, Mazzaglia P, Chia SY, et al.: The utility of peripheral thyrotropin mRNA in the diagnosis of follicular neoplasms and surveillance of thyroid cancers. Surgery 2007; 141: 137-146; discussion 146. (Pubitemid 46149880)
47. Baloch ZW, Livolsi VA,: Follicular-patterned lesions of the thyroid: The bane of the pathologist. Am J Clin Pathol 2002; 117: 143-150. (Pubitemid 34052484)
48. Zeiger MA, Dackiw AP,: Follicular thyroid lesions, elements that affect both diagnosis and prognosis. J Surg Oncol 2005; 89: 108-113. (Pubitemid 40315906)
49. Garnett MJ, Marais R,: Guilty as charged: B-RAF is a human oncogene. Cancer Cell 2004; 6: 313-319. (Pubitemid 39361432)
50. Cohen Y, Rosenbaum E, Clark DP, et al.: Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: A potential application for the preoperative assessment of thyroid nodules. Clin Cancer Res 2004; 10: 2761-2765. (Pubitemid 38509152)
51. Nikiforova MN, Nikiforov YE,: Molecular diagnostics and predictors in thyroid cancer. Thyroid 2009; 19: 1351-1361.
52. Repasky GA, Chenette EJ, Der CJ,: Renewing the conspiracy theory debate: Does Raf function alone to mediate Ras oncogenesis? Trends Cell Biol 2004; 14: 639-647. (Pubitemid 39440613)
53. Xing M,: Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid 2010; 20: 697-706.
54. Namba H, Rubin SA, Fagin JA,: Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol 1990; 4: 1474-1479. (Pubitemid 20356608)
55. Lemoine NR, Mayall ES, Wyllie FS, et al.: High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene 1989; 4: 159-164. (Pubitemid 19096939)
56. Suarez HG, du Villard JA, Severino M, et al.: Presence of mutations in all three ras genes in human thyroid tumors. Oncogene 1990; 5: 565-570.
57. Esapa CT, Johnson SJ, Kendall-Taylor P, et al.: Prevalence of Ras mutations in thyroid neoplasia. Clin Endocrinol (Oxf) 1999; 50: 529-535. (Pubitemid 29193238)
58. Arora N, Scognamiglio T, Zhu B, et al.: Do benign thyroid nodules have malignant potential? An evidence-based review. World J Surg 2008; 32: 1237-1246.
59. Tallini G, Asa SL,: RET oncogene activation in papillary thyroid carcinoma. Adv Anat Pathol 2001; 8: 345-354.
60. Ciampi R, Nikiforov YE,: RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology 2007; 148: 936-941.
61. Ishizaka Y, Kobayashi S, Ushijima T, et al.: Detection of retTPC/PTC transcripts in thyroid adenomas and adenomatous goiter by an RT-PCR method. Oncogene 1991; 6: 1667-1672. (Pubitemid 21924271)
62. Elisei R, Romei C, Vorontsova T, et al.: RET/PTC rearrangements in thyroid nodules: Studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults. J Clin Endocrinol Metab 2001; 86: 3211-3216. (Pubitemid 32673490)
63. Wirtschafter A, Schmidt R, Rosen D, et al.: Expression of the RET/PTC fusion gene as a marker for papillary carcinoma in Hashimoto's thyroiditis. Laryngoscope 1997; 107: 95-100. (Pubitemid 27045201)
64. Sheils OM, O'Eary JJ, Uhlmann V, et al.: ret/PTC-1 activation in Hashimoto thyroiditis. Int J Surg Pathol 2000; 8: 185-189.
65. Eberhardt NL, Grebe SK, McIver B, et al.: The role of the PAX8/PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancer. Mol Cell Endocrinol 2010; 321: 50-56.
66. Marques AR, Espadinha C, Catarino AL, et al.: Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 2002; 87: 3947-3952. (Pubitemid 34879553)
67. Dwight T, Thoppe SR, Foukakis T, et al.: Involvement of the PAX8/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors. J Clin Endocrinol Metab 2003; 88: 4440-4445. (Pubitemid 37153755)
68. French CA, Alexander EK, Cibas ES, et al.: Genetic and biological subgroups of low-stage follicular thyroid cancer. Am J Pathol 2003; 162: 1053-1060. (Pubitemid 36350651)
69. Townsley FM, Aristarkhov A, Beck S, et al.: Dominant-negative cyclin-selective ubiquitin carrier protein E2-C/UbcH10 blocks cells in metaphase. Proc Natl Acad Sci USA 1997; 94: 2362-2367. (Pubitemid 27136880)
70. Cleynen I, Van de Ven WJ,: The HMGA proteins: A myriad of functions (review). Int J Oncol 2008; 32: 289-305. (Pubitemid 351188295)
71. Cohen SB, Graham ME, Lovrecz GO, et al.: Protein composition of catalytically active human telomerase from immortal cells. Science 2007; 315: 1850-1853. (Pubitemid 46580145)
72. Greider CW, Blackburn EH,: Identification of a specific telomere terminal transferase activity in tetrahymena extracts. Cell 1985; 43: 405-413. (Pubitemid 16213265)
73. Kim NW, Piatyszek MA, Prowse KR, et al.: Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011-2015.
74. Capezzone M, Marchisotta S, Cantara S, et al.: Telomeres and thyroid cancer. Curr Genomics 2009; 10: 526-533.
75. Bartels CL, Tsongalis GJ,: MicroRNAs: Novel biomarkers for human cancer. Clin Chem 2009; 55: 623-631.
76. Kundel A, Zarnegar R, Kato M, et al.: Comparison of microarray analysis of fine needle aspirates and tissue specimen in thyroid nodule diagnosis. Diagn Mol Pathol 2010; 19: 9-14.
77. Cerutti JM, Delcelo R, Amadei MJ, et al.: A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression. J Clin Invest 2004; 113: 1234-1242. (Pubitemid 38544109)
78. Griffith OL, Chiu CG, Gown AM, et al.: Biomarker panel diagnosis of thyroid cancer: A critical review. Expert Rev Anticancer Ther 2008; 8: 1399-1413.
79. Fischer S, Asa SL,: Application of immunohistochemistry to thyroid neoplasms. Arch Pathol Lab Med 2008; 132: 359-372. (Pubitemid 351328811)
80. Chiu CG, Strugnell SS, Griffith OL, et al.: Diagnostic utility of galectin-3 in thyroid cancer. Am J Pathol 2010; 176: 2067-2081.
81. Bartolazzi A, Gasbarri A, Papotti M, et al.: Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet 2001; 357: 1644-1650. (Pubitemid 32568236)
82. Sheibani K, Esteban JM, Bailey A, et al.: Immunopathologic and molecular studies as an aid to the diagnosis of malignant mesothelioma. Hum Pathol 1992; 23: 107-116.
83. Moll R, Divo M, Langbein L,: The human keratins: Biology and pathology. Histochem Cell Biol 2008; 129: 705-733.
84. Teicher BA, Fricker SP,: CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 2010; 16: 2927-2931.
85. Castellone MD, Guarino V, De Falco V, et al.: Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas. Oncogene 2004; 23: 5958-5967. (Pubitemid 39093540)
86. He X, Wei Q, Zhang X, et al.: Immunohistochemical expression of CXCR4 in thyroid carcinomas and thyroid benign lesions. Pathol Res Pract 2010; 206: 712-715.
87. Saleh HA, Feng J, Tabassum F, et al.: Differential expression of galectin-3, CK19, HBME1, and Ret oncoprotein in the diagnosis of thyroid neoplasms by fine needle aspiration biopsy. Cytojournal 2009; 6: 18.
88. Gharib H, Papini E, Paschke R, et al.: American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: Executive Summary of recommendations. J Endocrinol Invest 2010; 33: 287-291.
89. British Thyroid Association RCoP: Guidelines for the management of thyroid cancer. Suffolk: The Lavenham Press; 2007.